Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04104672 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
A Phase 1 study of Advanced Pancreatic Cancer, sponsored by Arcus Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 196
- Enrollment target
- 14
- Study locations
NCT04104672 is a Phase 1 study of Advanced Pancreatic Cancer that is active but no longer recruiting, run by Arcus Biosciences. The registered enrollment target is 196 participants, above the 49-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (300% higher). The trial reports 14 study locations across 9 states.
The verdict
NCT04104672, a Phase 1 study of Advanced Pancreatic Cancer, is active but no longer recruiting, sponsored by Arcus Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 196 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Zimberelimab
- DRUG Nab-paclitaxel
- DRUG AB680
Study Locations (14)
New York
- NYU Cancer Institute - New York
- Columbia University - New York
- Memorial Sloan Kettering Cancer Center - New York
California
- The Angeles Clinic - Los Angeles
- UCLA Hematology Oncology - Santa Monica
Pennsylvania
- University of Pennsylvania - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- START San Antonio - San Antonio
Missouri
- Washington University School of Medicine - Siteman Cancer Center - St Louis
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Tennessee
- Sarah Canon Research Institute - Nashville
Washington
- Medical Oncology Associates - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2019-11-06 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04104672
The ClinicalTrials.gov registry entry for NCT04104672 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 49-participant average among 7 other Advanced Pancreatic Cancer trials with a reported enrollment target (300% higher). The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Gemcitabine is the first listed.
NCT04104672 reports 14 study locations spanning 9 distinct geographic areas - top geographies include New York, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04104672 about?
NCT04104672 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies". This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants...
What is the current status of trial NCT04104672?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 196 participants. The study started on 2019-11-06. Estimated completion is 2027-05.
What conditions does trial NCT04104672 study?
This clinical trial studies the following conditions: Advanced Pancreatic Cancer.
What interventions are being tested in trial NCT04104672?
The interventions under investigation include: Gemcitabine (DRUG), Zimberelimab (DRUG), Nab-paclitaxel (DRUG), AB680 (DRUG).
Who is sponsoring clinical trial NCT04104672?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04104672 being conducted?
This trial has 14 study locations across California, Missouri, New York, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
COMPLETED · Phase 1
-
1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.